Table of Contents
ISRN Neurology
Volume 2012 (2012), Article ID 410629, 7 pages
http://dx.doi.org/10.5402/2012/410629
Clinical Study

African Ancestry Is a Predictor Factor to Secondary Progression in Clinical Course of Multiple Sclerosis

Departamento de Neurologia, Hospital Universitário Gaffrée e Guinle, Rua Mariz e Barros 775, 2° andar, Maracanã-Tijuca, 20270-004 Rio de Janeiro, RJ, Brazil

Received 19 September 2012; Accepted 8 October 2012

Academic Editors: K. R. Pennypacker and J. E. Riggs

Copyright © 2012 Claudia Cristina Ferreira Vasconcelos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. G. Weinshenker, B. Bass, G. P. A. Rice et al., “The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability,” Brain, vol. 112, no. 1, pp. 133–146, 1989. View at Google Scholar · View at Scopus
  2. B. G. Weinshenker, B. Bass, G. P. A. Rice et al., “The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course,” Brain, vol. 112, no. 6, pp. 1419–1428, 1989. View at Google Scholar · View at Scopus
  3. S. J. Pittock, W. T. Mayr, R. L. McClelland et al., “Disability profile of MS did not change over 10 years in a population-based prevalence cohort,” Neurology, vol. 62, no. 4, pp. 601–606, 2004. View at Google Scholar · View at Scopus
  4. H. Tremlett, D. Paty, and V. Devonshire, “Disability progression in multiple sclerosis is slower than previously reported,” Neurology, vol. 66, no. 2, pp. 172–177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Confavreux, S. Vukusic, T. Moreau, and P. Adeleine, “Relapses and progression of disability in multiple sclerosis,” The New England Journal of Medicine, vol. 343, no. 20, pp. 1430–1438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Confavreux, S. Vukusic, and P. Adeleine, “Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process,” Brain, vol. 126, no. 4, pp. 770–782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Weinstock-Guttman, L. D. Jacobs, C. M. Brownscheidle et al., “Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium,” Multiple Sclerosis, vol. 9, no. 3, pp. 293–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. B. A. C. Cree, O. Khan, D. Bourdette et al., “Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis,” Neurology, vol. 63, no. 11, pp. 2039–2045, 2004. View at Google Scholar · View at Scopus
  9. R. T. Naismith, K. Trinkaus, and A. H. Cross, “Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review,” Multiple Sclerosis, vol. 12, no. 6, pp. 775–781, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Jeannin, V. Bourg, F. Berthier, and C. Lebrun, “Phenotypical aspects and clinical course of multiple sclerosis in 76 patients with a North African ethnic background followed at the Nice University Hospital,” Revue Neurologique, vol. 163, no. 4, pp. 440–447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. C. F. Vasconcelos, L. C. Santos Thuler, G. A. C. Dos Santos et al., “Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients,” Multiple Sclerosis, vol. 16, no. 5, pp. 597–603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. F. D. Lublin and S. C. Reingold, “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology, vol. 46, no. 4, pp. 907–911, 1996. View at Google Scholar · View at Scopus
  13. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker, “Revised diagnostic criteria for neuromyelitis optica,” Neurology, vol. 66, no. 10, pp. 1485–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. M. Poser, D. W. Paty, L. Scheinberg et al., “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Annals of Neurology, vol. 13, no. 3, pp. 227–231, 1983. View at Google Scholar · View at Scopus
  16. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  17. O. H. Kantarci and B. G. Weinshenker, “Natural history of multiple sclerosis,” Neurologic Clinics, vol. 23, no. 1, pp. 17–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Perini, C. Tagliaferri, M. Belloni, G. Biasi, and P. Gallo, “The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy,” Neurology, vol. 57, no. 1, pp. 158–159, 2001. View at Google Scholar · View at Scopus
  19. M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers, “The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease,” Brain, vol. 129, no. 3, pp. 584–594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. W. Paty and D. K. B. Li, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo- controlled trial,” Neurology, vol. 43, no. 4, pp. 662–667, 1993. View at Google Scholar · View at Scopus
  21. K. P. Johnson, B. R. Brooks, J. A. Cohen et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995. View at Google Scholar · View at Scopus
  22. European Study Group on interferon beta-1b in secondary progressive MS, “Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis,” The Lancet, vol. 352, no. 9139, pp. 1491–1497, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. G. P. A. Rice, M. Filippi, and G. Comi, “Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group,” Neurology, vol. 54, no. 5, pp. 1145–1155, 2000. View at Google Scholar · View at Scopus
  24. A. J. Coles, M. G. Wing, P. Molyneux et al., “Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis,” Annals of Neurology, vol. 46, no. 3, pp. 296–304, 1999. View at Google Scholar
  25. B. D. Trapp and K. A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri, “The contribution of demyelination to axonal loss in multiple sclerosis,” Brain, vol. 129, no. 6, pp. 1507–1516, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. F. D. Lublin, M. Baier, and G. Cutter, “Effect of relapses on development of residual deficit in multiple sclerosis,” Neurology, vol. 61, no. 11, pp. 1528–1532, 2003. View at Google Scholar · View at Scopus
  28. H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, and Y. Zhao, “Impact of multiple sclerosis relapses on progression diminishes with time,” Neurology, vol. 73, no. 20, pp. 1616–1623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Compston, “Making progress on the natural history of multiple sclerosis,” Brain, vol. 129, no. 3, pp. 561–563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Confavreux and S. Vukusic, “Age at disability milestones in multiple sclerosis,” Brain, vol. 129, no. 3, pp. 595–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Scalfari, A. Neuhaus, A. Degenhardt et al., “The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability,” Brain, vol. 133, no. 7, pp. 1914–1929, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Leray, J. Yaouanq, E. Le Page et al., “Evidence for a two-stage disability progression in multiple sclerosis,” Brain, vol. 133, no. 7, pp. 1900–1913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. G. Phadke, “Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis,” Brain, vol. 113, no. 6, pp. 1597–1628, 1990. View at Google Scholar · View at Scopus
  34. M. Koch, E. Kingwell, P. Rieckmann et al., “The natural history of secondary progressive multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 9, pp. 1039–1043, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Stankoff, S. Mrejen, A. Tourbah et al., “Age at onset determines the occurrence of the progressive phase of multiple sclerosis,” Neurology, vol. 68, no. 10, pp. 779–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Howard and V. J. Howard, “Ethnic disparities in stroke: The scope of the problem,” Ethnicity and Disease, vol. 11, no. 4, pp. 761–768, 2000. View at Google Scholar · View at Scopus
  37. M. R. Arbuckle, J. A. James, G. J. Dennis et al., “Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus,” Lupus, vol. 12, no. 2, pp. 99–106, 2003. View at Google Scholar
  38. M. A. De Jesus, M. Fujita, K. S. Kim et al., “Retrospective analysis of breast cancer among young African American females,” Breast Cancer Research and Treatment, vol. 78, no. 1, pp. 81–87, 2003. View at Google Scholar
  39. R. Govindarajan, R. V. Shah, L. G. Erkman, and L. F. Hutchins, “Racial differences in the outcome of patients with colorectal carcinoma,” Cancer, vol. 97, no. 2, pp. 493–498, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. B. A. Johnson, J. Wang, E. M. Taylor et al., “Multiple sclerosis susceptibility alleles in African Americans,” Genes and Immunity, vol. 11, no. 4, pp. 343–350, 2010. View at Publisher · View at Google Scholar · View at Scopus